Device Trial Radar · NCT04670536
The Degen Study: Post-market Clinical Follow-up on the PASS LP, PASS Degen and PASS Tulip Systems (PASS DEGEN)
Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
77
Actual
Start
May 17, 2018
Primary completion
May 22, 2024
Study completion May 22, 2024
Sponsor
- Lead sponsor
- Medicrea InternationalNot on our public-company list
- Sponsor type
- Industry
- First posted
- Dec 17, 2020
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this post-market clinical study is to evaluate the long-term safety and efficacy of the MEDICREA's systems PASS LP, PASS DEGEN, and PASS Tulip PRIME to treat degenerative diseases. This study is supporting the clinical evaluation report. From the standard-of-care perspective, the results of The Degen study are expected to contribute to a better understanding of expected safety and clinical outcomes from a short (intra- and peri-operative) to a medium-term follow-up (post-operatively).
Conditions
- Thoracolumbar Disc Degeneration
- Thoracolumbar Spondylolisthesis
- Spinal Deformity
- Spinal Degeneration
Interventions
PASS LP implantsDevice
Thoraco lumbar arthrodesis
PASS DEGENDevice
Thoraco lumbar arthrodesis
PASS TULIP PRIMEDevice
Thoraco lumbar arthrodesis
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participant Who Achieved Their Fusion at 24 MonthsTime frame: At 24months
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Clinique du Dos Bordeaux - Terrefort
Bruges, France
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.